Biodexa Pharmaceticals Current Debt

BDRX Stock   4.98  0.41  8.97%   
At this time, Biodexa Pharmaceticals' Short Term Debt is fairly stable compared to the past year. Net Debt To EBITDA is likely to rise to 1.06 in 2024, whereas Net Debt is likely to drop (5.8 M) in 2024. With a high degree of financial leverage come high-interest payments, which usually reduce Biodexa Pharmaceticals' Earnings Per Share (EPS).
 
Debt Ratio  
First Reported
2010-12-31
Previous Quarter
0.0125
Current Value
0.0119
Quarterly Volatility
0.39662882
 
Credit Downgrade
 
Yuan Drop
 
Covid
Given that Biodexa Pharmaceticals' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Biodexa Pharmaceticals is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Biodexa Pharmaceticals to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Biodexa Pharmaceticals is said to be less leveraged. If creditors hold a majority of Biodexa Pharmaceticals' assets, the Company is said to be highly leveraged.
Total Current Liabilities is likely to drop to about 3.8 M in 2024. Non Current Liabilities Total is likely to drop to about 280.2 K in 2024
  
Check out the analysis of Biodexa Pharmaceticals Fundamentals Over Time.
For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Biodexa Pharmaceticals Financial Rating

Biodexa Pharmaceticals financial ratings play a critical role in determining how much Biodexa Pharmaceticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Biodexa Pharmaceticals' borrowing costs.
Piotroski F Score
2
FrailView
Beneish M Score
 3.22 
Possible ManipulatorView

Biodexa Pharmaceticals Total Assets Over Time

Biodexa Pharmaceticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Biodexa Pharmaceticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Biodexa Pharmaceticals Debt Ratio

    
  1.19   
It appears most of the Biodexa Pharmaceticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Biodexa Pharmaceticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Biodexa Pharmaceticals, which in turn will lower the firm's financial flexibility.

Biodexa Net Debt

Net Debt

(5.78 Million)

Biodexa Pharmaceticals reported Net Debt of (5.51 Million) in 2023

Understaning Biodexa Pharmaceticals Use of Financial Leverage

Understanding the structure of Biodexa Pharmaceticals' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Biodexa Pharmaceticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last ReportedProjected for Next Year
Net Debt-5.5 M-5.8 M
Short and Long Term Debt Total464 K440.8 K
Short Term Debt169 K307.8 K
Net Debt To EBITDA 0.85  1.06 
Debt To Equity 0.02  0.02 
Interest Debt Per Share 1.30  1.23 
Debt To Assets 0.01  0.01 
Long Term Debt To Capitalization 0.20  0.18 
Total Debt To Capitalization 0.01  0.01 
Debt Equity Ratio 0.02  0.02 
Debt Ratio 0.01  0.01 
Cash Flow To Debt Ratio(99.96)(94.97)
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.